Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer
Open accessThe DOI matches its Crossref record; 153 of the 161 references it cites were found in a registry or an index; 18 of the 135 sources its claims cite were checked for support.
Abstract
Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment.
Overview
CoChat Summary
## TL;DR
This paper is a review of aminolevulinic acid (ALA) as a prodrug for photodynamic therapy (PDT) in cancer, explaining how exogenous ALA leads to protoporphyrin IX (PpIX) accumulation and selective tumor killing after light exposure. It argues that ALA-PDT is a highly promising, clinically approved strategy, but its effectiveness is limited by poor penetration, pain, light depth, and variable PpIX accumulation.
## Key findings
- Exogenous ALA bypasses normal heme-regulated control, causing PpIX to accumulate because ferrochelatase cannot convert it to heme quickly enough; light exposure after about 4–6 hours activates PpIX and generates cytotoxic singlet oxygen.
- Tumor selectivity is linked to heme-pathway differences: decreased ferrochelatase activity, limited iron availability, and increased activity of PpIX-producing enzymes such as ALAD, UROD, and PBGD contribute to higher PpIX in tumors than in normal cells.
- Reported clinical outcomes include 50%–100% complete responses for superficial basal cell carcinoma, 43% recurrence at 60 months, 100% response with no recurrence after 18 months in cutaneous T-cell lymphoma, and 68%–75% complete response after single MAL-PDT for actinic keratosis.
- The paper states that at least 77 ALA modifications and carriers have been reported to improve delivery, reflecting strong interest in overcoming ALA’s limited skin and tissue penetration.
## Methods
- Narrative review of the literature on ALA metabolism, pharmacokinetics, preclinical PDT studies, clinical indications, and ALA derivatives.
- Synthesizes prior experimental and clinical studies in multiple systems, including cell lines, mouse and rat models, and human clinical trials.
- Main analysis is qualitative: it compares reported mechanisms, delivery strategies, and treatment outcomes rather than presenting a new dataset or original statistical analysis.
## Limitations
- The paper states that ALA-PDT is limited by light hypersensitivity, inefficiency for large or metastatic tumors, pain during treatment, and limited tissue penetration.
- It also states that topical and even systemic ALA penetrate tissues only poorly, restricting efficacy; for topical use, PpIX fluorescence is seen only to a depth of 0.3 to 0.6 mm.
- Evident from the text: this is a review, so its conclusions depend on prior studies and are not based on a single controlled experiment or newly collected patient cohort.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 3 Not valid · 72 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Enhanced activity of enzymes leading to production of PpIX, such as ALAD [43], UROD [43], or PBGD [38,43,44] has also been observed in tumor cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Not checked — no full text of the sourcecites [43] Navone, 1990, Heme biosynthesis in human breast cancer--mimetic "in vitro" studies and some heme enzymic activity levels, Int. J. Biochem. source
- Partly supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Discussion (p. 681) reports increased PBG-D activity in malignant and premalignant oesophageal tissue compared with normal squamous epithelium, supporting the PBGD part of the citation. The paper reports measuring PBG-D and ferrochelatase, but the passages found do not report enhanced ALAD or UROD activity in tumor cells. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [44] Kondo, 1993, Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat, Cell. Biol. Toxicol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PpIX has been found to preferentially accumulate in tumor as compared with normal cells.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.4. Selectivity of PpIX Accumulation in Tumor Tissue in Response to ALA Administration
What the sources say
- Supportedcites [38] Hinnen, 1998, Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre)malignant lesions of the oesophagus, Br. J. Cancer source
The Discussion (p. 682) says the study's results provide evidence for selective PPIX accumulation between normal and neoplastic tissue of the oesophagus. This supports the claim that preferential tumour accumulation has been found, without implying it occurs in every tumour type. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [39] Krieg, 2000, Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro, Photochem. Photobiol. doi:10.1562/0031-8655(2000)072
- Not checked — no full text of the sourcecites [40] Hefti, 2011, Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity, Photochem. Photobiol. source
- Not checked — no full text of the sourcecites [41] Ohgari, 2005, Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: Relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin, Biochem. Pharmacol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 1987 ALA was used for the first time in photodynamic therapy as a porphyrin precursor for selective elimination of erythroleukaemic cells [89].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 6. Preclinical Studies with ALA
What the sources say
- Partly supportedcites [89] Malik, 1987, Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Summary (p. 589) reports that 5-ALA stimulated porphyrin synthesis in Friend erythroleukaemic cells and that light exposure selectively destroyed the cells. The paper does not establish that this was the first use of ALA in photodynamic therapy; that priority claim is unsupported by our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Enhancement of PDT effects has been also observed after removal of iron with different iron-chelating substances such as desferrioxamine [51] or CP94 [52].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 2. Metabolism of ALA > 2.5. Modifications of Heme Biosynthetic Pathway and Its Influence on ALA-PDT
What the sources say
- Supportedcites [51] Tan, 1997, Enhancement of photodynamic therapy in gastric cancer cells by removal of iron, Gut source
The Abstract (p. 1) of Tan et al. (1997) states 'PDT using ALA can be improved by removal of available iron with desferrioxamine', with 200 µmolar desferrioxamine trebling PPIX accumulation and low doses (0–30 µmolar) reducing cell viability after light exposure; the Discussion (QUANTITATION OF PORPHYRIN section) adds that adding iron abrogated the desferrioxamine effect, supporting iron removal as the mechanism. This covers the part of the citing sentence offered to this source (desferrioxamine); CP94 is carried on a separate citation [52] and is not mentioned anywhere in our copy. The source's demonstration is in an in vitro gastric cancer cell line (AGA) with ALA/PDT, and it notes a paradoxical protective effect at higher desferrioxamine doses ('J'-shaped curve, Conclusion), so the enhancement is dose-related rather than unconditional. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [52] Blake, 2010, The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells, Photochem. Photobiol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Compared with cryotherapy for actinic keratosis MAL-PDT was found to have a better or similar effectiveness (complete response rate 68%–75% after single treatment) [129,130].”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
What the sources say
- Partly supportedcites [129] Tarstedt, 2005, A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp, Acta Derm. Venereol. sourceExperimental — accuracy not yet measured
Our copy of Tarstedt et al. (Abstract) shows this was a head-to-head comparison of two MAL-PDT schedules (single treatment vs two treatments 1 week apart) in 211 patients with thin-to-moderately thick actinic keratoses of the face and scalp; there is no cryotherapy arm and no cryotherapy comparison anywhere in the text we hold (searched: cryotherapy, liquid nitrogen, freezing, comparison with previous studies). The single-treatment complete response figures it does report — 93% (87–97%) for thin lesions and 70% (60–78%) for thicker lesions — only partly fall inside the 68%–75% range the citing sentence attributes, and the 'better or similar effectiveness compared with cryotherapy' claim is not supported by this source. (LLM, conf=0.70)
- Not checked — no full text of the sourcecites [130] Freeman, 2003, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study, J. Dermatolog Treat. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims
Create a free account to see all 112 claims and to verify the 10 references still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 29
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ALA administered topically or systemically is non-selectively taken up into cells and metabolized into photosensitive PpIX by the resident enzyme machinery [8].”
From Photodynamic Therapy for Non-Melanoma Skin Cancers (2016) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 5. Comparison of ALA with Porphyrin-based Photosensitizers
“ALA is the only photosensitizer registered for topical use, particularly useful for the local treatment of superficial skin lesions.”
§ Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer > 7. Clinical Indications for ALA and Its Esters
“MAL was approved in the treatment of actinic keratosis and nonmelanoma skin cancers (basal cell carcinoma) in Australia, New Zealand and some European countries. MAL, administered in a form of a cream, 3 hours after application under occlusion is activated with red light usually in a total dose of 75 J/cm2.”
Citations
Cites
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Gomer, C. J. (1988) · Cited by 4,174
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707
Photodynamic therapy with endogenous protoporphyrin
Kennedy, J. C., Pottier, R. H., & Pross, D. C. (1990) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(90)85083-9 · Cited by 1,509 · cited 1×
“Since the very first topical application of ALA in the treatment of basal cell carcinoma in 1990 [8], the clinical use of ALA-PDT is still growing.”
BackgroundO’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Kennedy (1992) · doi:10.1016/1011-1344(92)85108-7 · Cited by 1,166
5-Aminolevulinic Acid-Based Photodynamic Therapy: Principles and Experimental Research
Peng, Q., Berg, K., Moan, J., Kongshaug, M., & Nesland, J. M. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb08549.x · Cited by 615 · cited 2×
“Subsequent illumination of the tumor site with red light activates PpIX, triggers the oxidative damage and induces cytotoxicity [6].”
BackgroundStructure and Biodistribution Relationships of Photodynamic Sensitizers*
Boyle, R. W., & Dolphin, D. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03093.x · Cited by 498
Biosynthesis of heme in mammals
Ajioka, R. S., Phillips, J. D., & Kushner, J. P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.05.005 · Cited by 493
Oxygen Consumption and Diffusion Effects in Photodynamic Therapy
Foster, T. H., Murant, R. S., Bryant, R. G., Knox, R. S., Gibson, S. L., & Hilf, R. (1991) · Radiation Research · doi:10.2307/3577919 · Cited by 400
The Role of Subcellular Localization in Initiation of Apoptosis by Photodynamic Therapy
Kessel, D., Luo, Y., Deng, Y., & Chang, C. K. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb08581.x · Cited by 343
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease
MORTON, C. A., WHITEHURST, C., MOSELEY, H., MCCOLL, J. H., MOORE, J. V., & MACKIE, R. M. (1996) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1996.d01-1076.x · Cited by 306
Koch, M., Breithaupt, C., Kiefersauer, R., Freigang, J., Huber, R., & Messerschmidt, A. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600189 · Cited by 299
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297
Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins
Malik, Z., & Lugaci, H. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.246 · Cited by 292
Freeman, M., Vinciullo, C., Francis, D., Spelman, L., Nguyen, R., Fergin, P., Thai, K., Murrell, D., Weightman, W., Anderson, C., et al. (2003) · Journal of Dermatological Treatment · doi:10.1080/09546630310012118 · Cited by 285 · cited 1×
“Compared with cryotherapy for actinic keratosis MAL-PDT was found to have a better or similar effectiveness (complete response rate 68%–75% after single treatment) [129,130].”
BackgroundDirect tumor damage mechanisms of photodynamic therapy.
Nowis, D., Makowski, M., Stokłosa, T., Legat, M., Issat, T., & Gołab, J. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3447 · Cited by 282
Self-citationOral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy
Loh, C., MacRobert, A., Bedwell, J., Regula, J., Krasner, N., & Bown, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.284 · Cited by 263
Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid
Grant, W. E., MacRobert, A., Bown, S. G., Hopper, C., & Speight, P. M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91347-o · Cited by 263 · cited 1×
“Moreover, ALA-PDT was shown to be an effective treatment for head and neck cancer, especially for superficial lesions [119].”
BackgroundTenhunen, R., Ross, M. E., Marver, H. S., & Schmid, R. (1970) · Biochemistry · doi:10.1021/bi00804a016 · Cited by 262
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy.
Ishizuka, M., Abe, F., Sano, Y., Takahashi, K., Inoue, K., Nakajima, M., Kohda, T., Komatsu, N., Ogura, S.-I., & Tanaka, T. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.029 · Cited by 255
Bedwell, J., MacRobert, A., Phillips, D., & Bown, S. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.175 · Cited by 253 · cited 1×
“concentration in tumors as compared with normal mucosa and normal muscle suggested more selective necrosis in tumors [93].”
BackgroundPhotodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik, M., & Dougherty, G. J. (1999) · PubMed · Cited by 250
Piacquadio, D. J., Chen, D. M., Farber, H. F., Fowler, Jr., Glazer, S. D., Goodman, J. J., Hruza, L. L., Jeffes, E. W. B., Ling, M. R., Phillips, T. J., et al. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.1.41 · Cited by 239 · cited 1×
“Complete response at 12 week was observed in above 80% of patients, while the negative effects of therapy, like skin sensitivity and light-burning, decreased or resolved 24 hours after the illumination [117].”
Background5‐Aminolevulinic Acid Derivatives in Photomedicine: Characteristics, Application and Perspectives
Fotinos, N., Campo, M. A., Popowycz, F., Gurny, R., & Lange, N. (2006) · Photochemistry and Photobiology · doi:10.1562/2006-02-03-ir-794 · Cited by 238 · cited 1×
“At least 77 various ALA modification and different carriers have been reported [68].”
BackgroundFan, K., Hopper, C., Speight, P. M., Buonaccorsi, G. A., MacRobert, A. J., & Bown, S. G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961001)78:7<1374::aid-cncr2>3.0.co;2-l · Cited by 229
The 2.0 A structure of human ferrochelatase, the terminal enzyme of heme biosynthesis.
(2001) · Nature Structural Biology · doi:10.1038/84152 · Cited by 227 · cited 1×
“The reaction occurs on the inner surface of the inner mitochondrial membrane [26].”
BackgroundMorton, C., Campbell, S., Gupta, G., Keohane, S., Lear, J., Zaki, I., Walton, S., Kerrouche, N., Thomas, G., Soto, P., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07470.x · Cited by 213
Hsieh, Y., Wu, C., Chang, C., & Yu, J. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10273 · Cited by 202
Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model
Castano, A. P., Mroz, P., Wu, M. X., & Hamblin, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709256105 · Cited by 201 · cited 1×
“cellular cytotoxicity, two other important factors contribute to the overall PDT effect: the vascular shutdown and local inflammatory reaction [1-4].”
BackgroundSelective accumulation of endogenously produced porphyrins in a liver metastasis model in rats
Van Hillegersberg, R., Van Den Berg, J. W. O., Kort, W. J., Terpstra, O. T., & Wilson, J. H. P. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90860-2 · Cited by 198 · cited 1×
“no augmentation was found in healthy livers [92].”
BackgroundTarstedt, M., Rosdahl, I., Berne, B., Svanberg, K., & Wennberg, A. (2005) · Acta Dermato-Venereologica · doi:10.1080/00015550510032887 · Cited by 196 · cited 1×
“Compared with cryotherapy for actinic keratosis MAL-PDT was found to have a better or similar effectiveness (complete response rate 68%–75% after single treatment) [129,130].”
BackgroundFritsch, C., Homey, B., Stahl, W., Lehmann, P., Ruzicka, T., & Sies, H. (1998) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1998.tb02492.x · Cited by 192 · cited 1×
“Moreover, the therapy is comparably or less painful and causes less systemic effects after local treatment [126-128].”
BackgroundOn the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation
Collaud, S., Juzeniene, A., Moan, J., & Lange, N. (2004) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011043352984 · Cited by 184
Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes.
Anderson, P. M., & Desnick, R. J. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50263-5 · Cited by 175 · cited 1×
“ALAD, also known as porphobilinogen synthase (PBGS) comprises four homodimers, each of them having one active site [13].”
BackgroundPorphycenes: Facts and Prospects in Photodynamic Therapy of Cancer
Stockert, J., Canete, M., Juarranz, A., Villanueva, A., Horobin, R., Borrell, J., Teixido, J., & Nonell, S. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780362934 · Cited by 173
Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus
Peters, F. P., Kara, M. A., Rosmolen, W. D., Aalders, M. C. G., ten Kate, F. J. W., Bultje, B. C., Krishnadath, K. K., Fockens, P., van Lanschot, J. J. B., van Deventer, S. J. H., et al. (2005) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(05)00063-5 · Cited by 172
Ohgari, Y., Nakayasu, Y., Kitajima, S., Sawamoto, M., Mori, H., Shimokawa, O., Matsui, H., & Taketani, S. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.019 · Cited by 165
Riddle, R. D., Yamamoto, M., & Engel, J. D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.3.792 · Cited by 163 · cited 1×
“In mammals, two isoforms of ALA synthase have been identified: ALAS1, which is a housekeeping enzyme and ALAS2, which is expressed only in erythroid precursors [12].”
BackgroundYoshida, T., & Kikuchi, G. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34708-7 · Cited by 163
Vinciullo, C., Elliott, T., Francis, D., Gebauer, K., Spelman, L., Nguyen, R., Weightman, W., Sheridan, A., Reid, C., Czarnecki, D., et al. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06484.x · Cited by 158 · cited 1×
“received a 90% of complete response after 3 months, which had decreased to 78% following next 18 months [134].”
BackgroundTschen, E. H., Wong, D. S., Pariser, D. M., Dunlap, F. E., Houlihan, A., Ferdon, M. B., & the Phase IV ALA-PDT Actinic Keratosis Study Group (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07520.x · Cited by 157 · cited 1×
“In phase IV clinical trials after 12 months of therapy the recurrence rate was 19% [118].”
BackgroundPharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood
Rick, K., Sroka, R. C., Stepp, H. G., Kriegmair, M., Huber, R. M., Jacob, K., & Baumgärtner, R. (1997) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/s1011-1344(97)00076-6 · Cited by 148
Ji, Z., Yang, G., Vasovič, V., Čunderlíková, B., Suo, Z., Nesland, J. M., & Peng, Q. (2006) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2006.03.006 · Cited by 139
Pain associated with aminolevulinic acid-photodynamic therapy of skin disease
Warren, C. B., Karai, L. J., Vidimos, A., & Maytin, E. V. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.048 · Cited by 136
Szeimies, R., Sassy, T., & Landthaler, M. (1994) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1994.tb05003.x · Cited by 132
De Rosa, F. S., Marchetti, J. M., Thomazini, J. A., Tedesco, A. C., & Bentley, M. V. L. B. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00213-8 · Cited by 131 · cited 1×
“It was also suggested that addition of dimethyl sulfoxide (DMSO) and ethylenediaminetetraacetic acid (EDTA) to ALA may enhance its delivery to hairless mice skin for topical PDT [77].”
BackgroundHinnen, P., de Rooij, F., van Velthuysen, M., Edixhoven, A., van Hillegersberg, R., Tilanus, H., Wilson, J., & Siersema, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.559 · Cited by 130
Moloney, F. J., & Collins, P. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07946.x · Cited by 128
Aminolevulinic acid: From its unique biological function to its star role in photodynamic therapy
Fukuda, H., Casas, A., & Batlle, A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.04.018 · Cited by 127
The metabolism of δ-aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N
Berlin, N. I., Neuberger, A., & Scott, J. J. (1956) · Biochemical Journal · doi:10.1042/bj0640080 · Cited by 126
Taketani, S., Kohno, H., Furukawa, T., & Tokunaga, R. (1995) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a124790 · Cited by 123
Guidelines for practical use of MAL‐PDT in non‐melanoma skin cancer
Christensen, E., Warloe, T., Kroon, S., Funk, J., Helsing, P., Soler, A., Stang, H., Vatne, Ø., & Mørk, C. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03430.x · Cited by 120
Apalla, Z., Sotiriou, E., Chovarda, E., Lefaki, I., Devliotou-Panagiotidou, D., & Ioannides, D. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09492.x · Cited by 116
Sinha, A. K., Anand, S., Ortel, B. J., Chang, Y., Mai, Z., Hasan, T., & Maytin, E. V. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603273 · Cited by 114
5-Aminolevulinic Acid-Conjugated Gold Nanoparticles for Photodynamic Therapy of Cancer
Khaing Oo, M. K., Yang, X., Du, H., & Wang, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.777 · Cited by 113 · cited 1×
“biocompatible gold (Au) and chitosan, was one of the solutions suggested to improve ALA delivery to the tumor [78,79].”
BackgroundPhotodynamic therapy for basal cell carcinoma: Clinical and pathological determinants of response
Fantini, F., Greco, A., Del Giovane, C., Cesinaro, A. M., Venturini, M., Zane, C., Surrenti, T., Peris, K., & Calzavara‐Pinton, P. G. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03877.x · Cited by 113 · cited 1×
“Therefore in the treatment of basal cell carcinoma (BCC) much better response is reached for superficial BCC than nodular BCC [132,133].”
BackgroundMunakata, H. (2004) · Journal of Biochemistry · doi:10.1093/jb/mvh112 · Cited by 113
Pretreatment to Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy
Gerritsen, M. J. P., Smits, T., Kleinpenning, M. M., van de Kerkhof, P. C. M., & van Erp, P. E. J. (2009) · Dermatology · doi:10.1159/000183753 · Cited by 113
Cell-type Specific Protoporphyrin IX Metabolism in Human Bladder Cancer in vitro¶
Krieg, R. C., Fickweiler, S., Wolfbeis, O. S., & Knuechel, R. (2007) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2000)0720226ctspim2.0.co2 · Cited by 113
Peng, Q., Evensen, J. F., Rimington, C., & Moan, J. E. (1987) · Cancer Letters · doi:10.1016/0304-3835(87)90096-6 · Cited by 112
Taber, S. W., Fingar, V. H., Coots, C. T., & Wieman, T. J. (1998) · PubMed · Cited by 110
Woodburn, K. W., Fan, Q., Miles, D., Kessel, D. H., Luo, Y., & Young, S. W. (1997) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1997.tb08579.x · Cited by 109
Forster, B., Klein, A., Szeimies, R., & Maisch, T. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01093.x · Cited by 108 · cited 1×
“Other parameters that affect PpIX accumulation include pH [63-65], oxygen availability [63,66], illumination conditions, or thickness of striatum corneum [67].”
BackgroundRegulation of 5-aminolevulinate synthase mRNA in different rat tissues.
Srivastava, G., Borthwick, I. A., Maguire, D. J., Elferink, C. J., Bawden, M. J., Mercer, J. F., & May, B. K. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60700-8 · Cited by 107 · cited 1×
“Moreover, there is evidence that heme not only regulates ALAS1 mitochondrial import but also attenuates its transcription [36,37].”
BackgroundTerminal steps of haem biosynthesis
Dailey, H. A. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300590 · Cited by 105
Navone, N. M., Polo, C. F., Frisardi, A. L., Andrade, N. E., & del C. Baille, A. M. (1990) · International Journal of Biochemistry · doi:10.1016/0020-711x(90)90230-z · Cited by 103
The mitochondrial localization of coproporphyrinogen III oxidase
Grandchamp, B., Phung, N., & Nordmann, Y. (1978) · Biochemical Journal · doi:10.1042/bj1760097 · Cited by 98
Mang, T. S., Allison, R., Hewson, G., Snider, W., & Moskowitz, R. (1998) · PubMed · Cited by 98
Rat liver cytochrome P-450b, P-420b, and P-420c are degraded to biliverdin by heme oxygenase
Kutty, R. K., Daniel, R. F., Ryan, D. E., Levin, W., & Maines, M. D. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90492-4 · Cited by 95
Photobleaching-based Dosimetry Predicts Deposited Dose in ALA-PpIX PDT of Rodent Esophagus
Sheng, C., Hoopes, P. J., Hasan, T. G., et al. (2007) · Photochemistry and Photobiology · doi:10.1562/2006-09-07-ra-1033 · Cited by 94
Foley, P., Freeman, M., Menter, A., Siller, G., El‐Azhary, R. A., Gebauer, K., Lowe, N. J., Jarratt, M. T., Murrell, D. F., Rich, P., et al. (2009) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2008.04022.x · Cited by 92
Taketani, S., Kohno, H., Okuda, M., Furukawa, T., & Tokunaga, R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37318-0 · Cited by 88 · cited 3×
“is transported to the intermembrane space of mitochondria probably by peripheral-type benzodiazepine receptors (PBR) [18,19].”
BackgroundAngell-Petersen, E., Spetalen, S., Madsen, S. J., Sun, C.-H., Peng, Q., Carper, S. W., Sioud, M., & Hirschberg, H. (2006) · Journal of Neurosurgery · doi:10.3171/jns.2006.104.1.109 · Cited by 85
Wyld, L., Reed, M., & Brown, N. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.265 · Cited by 82 · cited 1×
“Other parameters that affect PpIX accumulation include pH [63-65], oxygen availability [63,66], illumination conditions, or thickness of striatum corneum [67].”
BackgroundThe Oxygen and Carbon Monoxide Reactions of Heme Oxygenase
Migita, C. T., Matera, K. M., Ikeda-Saito, M., Olson, J. S., Fujii, H., Yoshimura, T., Zhou, H., & Yoshida, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.2.945 · Cited by 82
Zane, C., Venturini, M., Sala, R., & Calzavara‐Pinton, P. (2006) · Photodermatology, Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2006.00246.x · Cited by 81
Miyake, M., Ishii, M., Kawashima, K., Kodama, T., Sugano, K., Fujimoto, K., & Hirao, Y. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00543.x · Cited by 79
5-ALA mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase
Ji, H.-T., Chien, L.-T., Lin, Y.-H., Chien, H.-F., & Chen, C.-T. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-91 · Cited by 79
Chen, H. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.12.010 · Cited by 77
Dailey, T. A., & Dailey, H. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13658 · Cited by 76
Purification and characterization of bovine hepatic uroporphyrinogen decarboxylase
Straka, J. G., & Kushner, J. P. (1983) · Biochemistry · doi:10.1021/bi00289a009 · Cited by 76 · cited 1×
“Uroporphyrinogen decarboxylase (UROD) catalyzes decarboxylation of all four acetate side chains of uroporphyrinogen III to methyl groups [17].”
BackgroundAbels, C., Heil, P., Dellian, M., Kuhnle, G., Baumgartner, R., & Goetz, A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.406 · Cited by 76
Dalton, J. T., Yates, C. R., Yin, D., Straughn, A., Marcus, S. L., Golub, A. L., & Meyer, M. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.507 · Cited by 75
Transcriptional Regulation of the Human Erythroid 5-Aminolevulinate Synthase Gene
Surinya, K. H., Cox, T. C., & May, B. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26585 · Cited by 74
Coors, E. A., & von den Driesch, P. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)00868-5 · Cited by 74 · cited 1×
“On the other hand, in the treatment of cutaneous T cell lymphoma Coors and colleagues were able to achieve 100% response with no recurrence after 18 months [115].”
BackgroundDosimetry considerations in phototherapy
Profio, A. E., & Doiron, D. R. (1981) · Medical Physics · doi:10.1118/1.594932 · Cited by 72
Souza, C. S., Felicio, L. B. A., Ferreira, J., Kurachi, C., Bentley, M. V. B., Tedesco, A. C., & Bagnato, V. S. (2009) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2009.09.001 · Cited by 71
Kondo, M., Hirota, N., Takaoka, T., & Kajiwara, M. (1993) · Cell Biology and Toxicology · doi:10.1007/bf00755143 · Cited by 69 · cited 2×
“Similar effects have been presented for inhibition of PBGD with Pb2+ [46].”
BackgroundSieron, A., Namyslowski, G., Misiolek, M., Adamek, M., & Kawczyk-Krupka, A. (2001) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s004050100347 · Cited by 65 · cited 1×
“patients with oral cavity, oral verrucous hyperplasia, larynx and hypopharynx carcinoma [120-122].”
BackgroundMalik, Z., & Djaldetti, M. (1979) · Cell Differentiation · doi:10.1016/0045-6039(79)90049-6 · Cited by 64
Inoue, K., Karashima, T., Kamada, M., Shuin, T., Kurabayashi, A., Furihata, M., Fujita, H., Utsumi, K., & Sasaki, J. (2009) · Pathobiology · doi:10.1159/000245896 · Cited by 64
Delfau‐Larue, M., Pavel Martasek, E., & Grandchamp, B. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.8.1325 · Cited by 64
Merclin, N., Bender, J., Sparr, E., Guy, R. H., Ehrsson, H., & Engström, S. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.025 · Cited by 63 · cited 1×
“In vitro experiments demonstrated lipid sponge forms (thermodynamically stable, amphiphilic liquid) as a potential carrier for transdermal drug delivery [76].”
Background5‐Aminolevulinic Acid Photosensitization of Dysplastic Barrett's Esophagus: A Pharmacokinetic Study
Ackroyd, R., Brown, N., Vernon, D., Roberts, D., Stephenson, T., Marcus, S., Stoddard, C., & Reed, M. (1999) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1999.tb08266.x · Cited by 62
Yow, C. M. N., Wong, C. K., Huang, Z. W., & Ho, R. J. Y. (2007) · Liver International · doi:10.1111/j.1478-3231.2006.01412.x · Cited by 61
Jordan, P. M., & Seehra, J. S. (1979) · FEBS Letters · doi:10.1016/0014-5793(79)80853-4 · Cited by 60
Tan, W. C., Fulljames, C., Stone, N., Dix, A. J., Shepherd, N., Roberts, D. J. H., Brown, S. B., Krasner, N., & Barr, H. (1999) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(99)00129-3 · Cited by 60 · cited 1×
“effective in eradicating high-grade dysplasia than in treatment of early esophagus cancer [124,125].”
Background(2003) · PubMed · Cited by 60
Self-citationColorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles
Yang, S.-J., Shieh, M.-J., Lin, F.-H., Lou, P.-J., Peng, C.-L., Wei, M.-F., Yao, C.-J., Lai, P.-S., & Young, T.-H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.014 · Cited by 56 · cited 1×
“biocompatible gold (Au) and chitosan, was one of the solutions suggested to improve ALA delivery to the tumor [78,79].”
BackgroundAmo, T., Kawanishi, N., Uchida, M., Fujita, H., Oyanagi, E., Utsumi, T., Ogino, T., Inoue, K., Shuin, T., Utsumi, K., et al. (2009) · Cell Biochemistry and Function · doi:10.1002/cbf.1603 · Cited by 56
Approaches to improve photodynamic therapy of cancer
Firczuk, M. (2011) · Frontiers in Bioscience · doi:10.2741/3684 · Cited by 55 · cited 1×
“cellular cytotoxicity, two other important factors contribute to the overall PDT effect: the vascular shutdown and local inflammatory reaction [1-4].”
BackgroundSelf-citationEvaluation of the penetration of 5‐aminolevulinic acid through basal cell carcinoma: a pilot study
Ahmadi, S., McCarron, P. A., Donnelly, R. F., Woolfson, A. D., & McKenna, K. (2004) · Experimental Dermatology · doi:10.1111/j.0906-6705.2004.00181.x · Cited by 55
Iinuma, S., Bachor, R., Flotte, T., & Hasan, T. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67726-7 · Cited by 55
Christensen, E., Skogvoll, E., Viset, T., Warloe, T., & Sundstrøm, S. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02946.x · Cited by 54
Casas, A., Perotti, C., Saccoliti, M., Sacca, P., Fukuda, H., & del C Batlle, A. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600144 · Cited by 52
Hefti, M., Holenstein, F., Albert, I., Looser, H., & Luginbuehl, V. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2010.00821.x · Cited by 52
The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX‐induced PDT of Cultured Human Glioma Cells
Blake, E., & Curnow, A. (2010) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2010.00770.x · Cited by 51
Inoue, H., Kajimoto, Y., Shibata, M.-A., Miyoshi, N., Ogawa, N., Miyatake, S.-I., Otsuki, Y., & Kuroiwa, T. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9325-8 · Cited by 50
Iinuma, S., Bachor, R., Flotte, T., & Hasan, T. (1995) · The Journal of Urology · doi:10.1097/00005392-199503000-00078 · Cited by 50
Kuželová, K., Grebeňová, D., Pluskalová, M., Marinov, I., & Hrkal, Z. (2004) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2003.07.007 · Cited by 50
Krieg (2000) · Pure Amsterdam UMC · doi:10.1562/0031-8655(2000)072 · Cited by 50
Coproporphyrinogen oxidase. II. Reaction mechanism and role of tyrosine residues on the activity.
Yoshinaga, T., & Sano, S. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85556-4 · Cited by 49
Wennberg, A.-M., Larkö, O., Lönnroth, P., Larson, G., & Krogstad, A.-L. (2000) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2000.00652.x · Cited by 48
Juzeniene, A., Juzenas, P., Kaalhus, O., Iani, V., & Moan, J. (2007) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2002)0760452teoaop2.0.co2 · Cited by 48
Valentine, R. M., Ibbotson, S. H., Brown, C. T. A., Wood, K., & Moseley, H. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2010.00829.x · Cited by 47
Obwegeser, A., Jakober, R., & Kostron, H. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.569 · Cited by 44
Kruijt, B., de Bruijn, H. S., den Heuvel, A. V. D. P., et al. (2008) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2008.00379.x · Cited by 43
Sequence of the reaction of heme catabolism catalyzed by the microsomal heme oxygenase system
Yoshida, T., & Kikuchi, G. (1974) · FEBS Letters · doi:10.1016/0014-5793(74)80481-3 · Cited by 41
The influence of temperature on photodynamic cell killing in vitro with 5-aminolevulinic acid
Juzeniene, A., Juzenas, P., Bronshtein, I., Vorobey, A., & Moan, J. (2006) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2006.02.009 · Cited by 41
The potential role for photodynamic therapy in the management of upper gastrointestinal disease
Barr, H., Dix, A. J., Kendall, C., & Stone, N. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00936.x · Cited by 40 · cited 1×
“5 times greater in mucosa then in muscles [123].”
BackgroundComparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma
Dögnitz, N., Salomon, D., Zellweger, M., Ballini, J.-P., Gabrecht, T., Lange, N., van den Bergh, H., & Wagnières, G. (2008) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2008.07.012 · Cited by 39
Precise detection of lymph node metastases in mouse rectal cancer by using 5‐aminolevulinic acid
Murayama, Y., Harada, Y., Imaizumi, K., Dai, P., Nakano, K., Okamoto, K. K., Otsuji, E., & Takamatsu, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24707 · Cited by 39
Boere, I. A., Robinson, D. J., de Bruijn, H. S., Kluin, J., Tilanus, H. W., Sterenborg, H. J. C. M., & de Bruin, R. W. F. (2006) · Photochemistry and Photobiology · doi:10.1562/2006-01-03-ra-763 · Cited by 38
Tunstall, R. G., Barnett, A. A., Schofield, J., Griffiths, J., Vernon, D. I., Brown, S. B., & Roberts, D. J. H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600460 · Cited by 37
Rodriguez, L., de Bruijn, H. S., Di Venosa, G., Mamone, L., Robinson, D. J., Juarranz, A., Batlle, A., & Casas, A. (2009) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2009.07.001 · Cited by 37
Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers
Wakui, M., Yokoyama, Y., Wang, H., Shigeto, T., Futagami, M., & Mizunuma, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0761-7 · Cited by 35
Docherty, J. C., Firneisz, G. D., & Schacter, B. A. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90241-8 · Cited by 34
Shoolingin-Jordan, P. M., Al-Dbass, A., McNeill, L. A., Sarwar, M., & Butler, D. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310731 · Cited by 34
Lee, J. B., Choi, J. Y., Chun, J. S., Yun, S. J., Lee, S. C., Oh, J., & Park, H. R. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08611.x · Cited by 32
The pH dependency of protoporphyrin IX formation in cells incubated with 5-aminolevulinic acid
Bech, Ø., Berg, K., & Moan, J. (1997) · Cancer Letters · doi:10.1016/s0304-3835(96)04558-2 · Cited by 32
Enhancement of photodynamic therapy in gastric cancer cells by removal of iron.
Tan, W. C., Krasner, N., O'Toole, P., & Lombard, M. (1997) · Gut · doi:10.1136/gut.41.1.14 · Cited by 31 · cited 1×
“Enhancement of PDT effects has been also observed after removal of iron with different iron-chelating substances such as desferrioxamine [51] or CP94 [52].”
BackgroundPhotodynamic therapy of eyelid basal cell carcinoma
Kotimäki, J. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03195.x · Cited by 31
Lee, T. K., Baron, E. D., & Foster, T. H. (2008) · Journal of Biomedical Optics · doi:10.1117/1.2939068 · Cited by 30
Inhibition of Escherichia coli porphobilinogen synthase using analogs of postulated intermediates
Jarret, C., Stauffer, F., Henz, M. E., Marty, M., Lüönd, R. M., Bobálová, J., Schürmann, P., & Neier, R. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00089-2 · Cited by 26 · cited 8×
“Dipyrromethane is a co-factor covalently bound to the enzyme and consists of two PBG molecules.”
BackgroundInfluential(1997) · PubMed · Cited by 24
An (2002) · doi:10.1562/0031-8655(2002)076 · Cited by 24
Verteporfin infusion-associated pain
Borodoker, N., Spaide, R. F., Maranan, L. C., et al. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01341-1 · Cited by 23
Uptake and kinetics of 5-aminolevulinic acid in oral squamous cell carcinoma
Uekusa, M., Omura, K., Nakajima, Y., Hasegawa, S., Harada, H., Morita, K.-I., & Tsuda, H. (2010) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2009.11.024 · Cited by 22
Grebeňová, D., Halada, P., Stulík, J., Havlíček, V., & Hrkal, Z. (2000) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2000)0720016pcihlc2.0.co2 · Cited by 22
Chahinian, A. P., Mandeli, J., Gluck, H., Naim, H., Teirstein, A. S., & Holland, J. F. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199802)67:2<90::aid-jso4>3.0.co;2-g · Cited by 22
Topical Bioadhesive Patch Systems Enhance Selectivity of Protoporphyrin IX Accumulation
Donnelly, R. F., Ma, L., Juzenas, P., Lani, V., McCarron, P. A., Woolfson, A. D., & Moan, J. (2006) · Photochemistry and Photobiology · doi:10.1562/2005-08-08-ra-641 · Cited by 22
Comparation of liposomal formulations of ALA Undecanoyl ester for its use in photodynamic therapy
Venosa, G. M. D., Bruno, L. H., Fukuda, H., Tesoriero, M. V. D., Rodríguez, L., Mamone, L. A., MacRobert, A. J., Casas, A. G., & Batlle, A. M. D. C. (2009) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2009.06.001 · Cited by 20
Silencing of ALA dehydratase affects ALA-photodynamic therapy efficacy in K562 erythroleukemic cells
Feuerstein, T., Schauder, A., & Malik, Z. (2009) · Photochemical & Photobiological Sciences · doi:10.1039/b9pp00007k · Cited by 19
Piot, B., Rousset, N., Lenz, P., Eléouet, S., Carré, J., Vonarx, V., Bourré, L., & Patrice, T. (2001) · The Laryngoscope · doi:10.1097/00005537-200112000-00026 · Cited by 17 · cited 1×
“Other parameters that affect PpIX accumulation include pH [63-65], oxygen availability [63,66], illumination conditions, or thickness of striatum corneum [67].”
BackgroundThe effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma
Grönlund‐Pakkanen, S., Wahlfors, J., Talja, M., Kosma, V. ‐., Pakkanen, T. M., Ala‐Opas, M., Alhava, E., & Moore, R. B. (2003) · BJU International · doi:10.1046/j.1464-410x.2003.04290.x · Cited by 14
Manivasager, V., Heng, P. W. S., Hao, J., Zheng, W., Soo, K. C., & Olivo, M. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.5.1003 · Cited by 14
Bergmann, F., Stepp, H. G., Metzger, R., et al. (2008) · Pediatric Surgery International · doi:10.1007/s00383-008-2275-9 · Cited by 14
Pudroma, X., Moan, J., Ma, L., Iani, V., & Juzeniene, A. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00863.x · Cited by 11 · cited 1×
“ALA-induced porphyrin accumulation, approximately 100 times less concentration of ALA heptyl ester is required [71].”
Background(1990) · PubMed · Cited by 9
Regulation of Porphyrin Synthesis and Photodynamic Therapy in Heavy Metal Intoxication
Grinblat, B., Pour, N., & Malik, Z. (2006) · Journal of Environmental Pathology, Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v25.i1-2.80 · Cited by 7
5-Aminolevulinic acid-based photodynamic therapy
(1997) · doi:10.1002/(sici)1097-0142(19970615)79:12<2282::aid-cncr2>3.0.co;2-o
Cited by
BODIPY dyes in photodynamic therapy
Kamkaew, A., Lim, S. H., Lee, H. B., Kiew, L. V., Chung, L. Y., & Burgess, K. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35216h · Cited by 2,104
Wu, G., Zhang, J., Zhao, Q., Zhuang, W., Ding, J., Zhang, C., Gao, H., Pang, D., Pu, K., & Xie, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201913700 · Cited by 269
Photodynamic Therapy: A Compendium of Latest Reviews
Algorri, J. F., Ochoa, M., Roldán-Varona, P., Rodríguez-Cobo, L., & López-Higuera, J. M. (2021) · Cancers · doi:10.3390/cancers13174447 · Cited by 263
Dias, L. D., Blanco, K. C., Mfouo-Tynga, I. S., Inada, N. M., & Bagnato, V. S. (2020) · Journal of Photochemistry and Photobiology C: Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2020.100384 · Cited by 251
Extracellular Metabolites from Industrial Microalgae and Their Biotechnological Potential
Liu, L., Pohnert, G., & Wei, D. (2016) · Marine Drugs · doi:10.3390/md14100191 · Cited by 193
“5-Aminolevulinic acid (ALA), which is a precursor of tetrapyrroles such as chlorophyll, haem, and vitamin B12, is used as a degradable insecticide and growth-promoting factor for plants [97].”
Background
Metadata
- Authors
- Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wańczyk, M., Bojarczuk, K., & Golab, J.
- Affiliations
- Medical University of Warsaw (PL)
- Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2011-05-19
- Volume
- 16
- Issue
- 5
- Pages
- 4140-4164
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6263343
- OpenAlex
- W1976436613
- Semantic Scholar
- 4c745297bf1ff574274bed2dbd865f2a7d5cc6ee
- Cited by
- 265
- References
- 161
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 28 · 2023: 19 · 2022: 14 · 2021: 24 · 2020: 36 · 2019: 23 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 10 · 2014: 13 · 2013: 4 · 2012: 9
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundacja na rzecz Nauki Polskiej
- Servier
- European Regional Development Fund (POIG. 01.01.02-00-008/08)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Porphyrin Metabolism and Disorders
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- 5-aminolevulinic acid, photodynamic therapy, prodrugs, protoporphyrin IX, photosensitizers, ferrochelatase, heme biosynthesis, cancer therapy, heme oxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.